The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Abstract
Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melzack, R., & Wall, P. D. (1965) · Science · doi:10.1126/science.150.3699.971 · Cited by 11,090
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483
A classification of chronic pain for ICD-11
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2015) · Pain · doi:10.1097/j.pain.0000000000000160 · Cited by 2,822
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079 · cited 1×
“Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high social and economic burden.(50) Anxiety is an emotional disorder characterized by feelings of tension, worried thoughts and changes such as increased blood pressure and heart rate.”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Neuronal circuits for fear and anxiety
Tovote, P., Fadok, J. P., & Lüthi, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3945 · Cited by 1,786
Chronic pain: a review of its epidemiology and associated factors in population-based studies
Mills, S. E. E., Nicolson, K. P., & Smith, B. H. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.03.023 · Cited by 1,728
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels
Perez-Reyes, E. (2003) · Physiological Reviews · doi:10.1152/physrev.00018.2002 · Cited by 1,652
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216 · cited 1×
“Opioids remain the keystone for the treatment of moderate to severe cancer pain.(133) Evidence for pain control with CBD in the cancer setting comes from a Phase 2 study that recruited 177 patients with cancer pain, who experienced inadequate analgesia despite chronic opioid dosing(134) (Table 2).”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“First-line antipsychotic drugs for schizophrenia act by blocking the central dopamine (DA) D2 receptors via receptor antagonism.(40) However, up to one-third of patients are unresponsive to these drugs.”
BackgroundDe Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
Russo, E. B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790144 · Cited by 621
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Freedman, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035458 · Cited by 587
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 560
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
Martin, E. I., Ressler, K. J., Binder, E., & Nemeroff, C. B. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.004 · Cited by 557
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6382 · Cited by 497
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 445
Gottesmann, C. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00034-9 · Cited by 439
Cannabidiol in Anxiety and Sleep: A Large Case Series
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019) · The Permanente Journal · doi:10.7812/tpp/18-041 · Cited by 432
COVID-19 pandemic—a focused review for clinicians
Cevik, M., Bamford, C. G. G., & Ho, A. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.023 · Cited by 392
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711351114 · Cited by 378
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
De Petrocellis, L., Vellani, V., Schiano-Moriello, A., Marini, P., Magherini, P. C., Orlando, P., & Di Marzo, V. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134809 · Cited by 336
De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott, C., Izzo, A. A., & Di Marzo, V. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02338.x · Cited by 323
Current perspectives of the roles of the central norepinephrine system in anxiety and depression
Goddard, A. W., Ball, S. G., Martinez, J., Robinson, M. J., Yang, C. R., Russell, J. M., & Shekhar, A. (2010) · Depression and Anxiety · doi:10.1002/da.20642 · Cited by 316
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14440 · Cited by 316
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J. M., Miyauchi, J. T., Tsirka, S. E., Ojima, I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618447 · Cited by 312
Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.057 · Cited by 312
5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305
Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016) · European Journal of Pain · doi:10.1002/ejp.818 · Cited by 300
Neuroimaging in social anxiety disorder: a systematic review of the literature
Freitas-Ferrari, M. C., Hallak, J. E. C., Trzesniak, C., Filho, A. S., Machado-de-Sousa, J. P., Chagas, M. H. N., Nardi, A. E., & Crippa, J. A. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.028 · Cited by 298
Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 291
Possible endocannabinoid control of colorectal cancer growth
Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M. G., Cosenza, V., D’argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00881-3 · Cited by 287
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 285
Inflammation, Cancer and Immunity—Implication of TRPV1 Channel
Bujak, J. K., Kosmala, D., Szopa, I. M., Majchrzak, K., & Bednarczyk, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01087 · Cited by 284
The endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
Cannabis and Pain: A Clinical Review
Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0017 · Cited by 281
Thiele, E. A., Bebin, E. M., Bhathal, H., Jansen, F. E., Kotulska, K., Lawson, J. A., O'Callaghan, F. J., Wong, M., Sahebkar, F., Checketts, D., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4607 · Cited by 281
Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061002 · Cited by 271
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707399 · Cited by 266
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
The Role of GABA in the Pathophysiology and Treatment of Anxiety Disorders
Nemeroff, C. B., MD, & PhD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4169 · Cited by 263
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., & Tan, G. D. (2016) · Diabetes Care · doi:10.2337/dc16-0650 · Cited by 262
The Religious and Medicinal Uses of Cannabis in China, India and Tibet
Touw, M. (1981) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1981.10471447 · Cited by 261
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255
Cannabidiol (CBD) as a Promising Anti-Cancer Drug
Seltzer, E. S., Watters, A. K., MacKenzie, D., Granat, L. M., & Zhang, D. (2020) · Cancers · doi:10.3390/cancers12113203 · Cited by 247
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
White, C. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1387 · Cited by 246
Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., Schnakenberg Martin, A. M., Thurnauer, H., Davies, A., D’Souza, D. C., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4885-9 · Cited by 242
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019) · Molecules · doi:10.3390/molecules24081459 · Cited by 238
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
Cannabidiol as potential anticancer drug
Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04298.x · Cited by 230
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1177-4 · Cited by 229
Russo, E. B., Guy, G. W., & Robson, P. J. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228
Ramer, R., & Hinz, B. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm268 · Cited by 222
Endocannabinoids and related N-acylethanolamines: biological activities and metabolism
Tsuboi, K., Uyama, T., Okamoto, Y., & Ueda, N. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0086-5 · Cited by 221
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., & Desprez, P.-Y. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0371 · Cited by 220
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., & Gallily, R. (2006) · Autoimmunity · doi:10.1080/08916930500356674 · Cited by 215
McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P. S., & Nagarkatti, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023937 · Cited by 211
De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C. G., Cristino, L., Orlando, P., & Di Marzo, V. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02027.x · Cited by 210
Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders
Scuderi, C., Filippis, D. D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2009) · Phytotherapy Research · doi:10.1002/ptr.2625 · Cited by 209
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 207
Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol
Ross, H. R., Napier, I., & Connor, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707104200 · Cited by 199
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., Oyarzabal, J., Canela, E. I., Lanciego, J. L., Nadal, X., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00744 · Cited by 199
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., & Parolaro, D. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6156-x · Cited by 196
D'Souza, D. C., Cortes-Briones, J., Creatura, G., Bluez, G., Thurnauer, H., Deaso, E., Bielen, K., Surti, T., Radhakrishnan, R., Gupta, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30427-9 · Cited by 195
Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., Di Marzo, V., & Izzo, A. A. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0856-x · Cited by 191
The endocannabinoid signaling system in cancer
Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C., & Bifulco, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.003 · Cited by 182
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol
Morales, P., Reggio, P. H., & Jagerovic, N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00422 · Cited by 178
Craske, M. G., Rauch, S. L., Ursano, R., Prenoveau, J., Pine, D. S., & Zinbarg, R. E. (2011) · Focus · doi:10.1176/foc.9.3.foc369 · Cited by 176
Capano, A., Weaver, R., & Burkman, E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2019.1685298 · Cited by 176
Ramer, R., Merkord, J., Rohde, H., & Hinz, B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.007 · Cited by 175
Kicman, A., & Toczek, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186740 · Cited by 172
Durán, M., Pérez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farré, M., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03743.x · Cited by 166
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., Mecha, M., Mestre, L., Fiebich, B. L., Cantarero, I., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9399-3 · Cited by 165
Shannon, S. M., & Opila-Lehman, J. (2016) · The Permanente Journal · doi:10.7812/tpp/16-005 · Cited by 165
Emerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 164
Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells
Jeong, S., Yun, H. K., Jeong, Y. A., Jo, M. J., Kang, S. H., Kim, J. L., Kim, D. Y., Park, S. H., Kim, B. R., Na, Y. J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.011 · Cited by 164
Grimison, P., Mersiades, A., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.020 · Cited by 162
Delta opioid receptors in brain function and diseases
Chu Sin Chung, P., & Kieffer, B. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.003 · Cited by 159
Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy
Catterall, W. A. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2314-9 · Cited by 159
Cannabinoids, Endocannabinoids and Sleep
Kesner, A. J., & Lovinger, D. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00125 · Cited by 150
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 147
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143 · cited 1×
“Previously, there were some excellent reviews on CBD, such as pain management,30–32 CNS disorders,(33) anticancer,(34,35) pharmacology and pharmacokinetics (PK)(5,36) and clinical trials.(32,37,38) This review will discuss the molecular mechanisms of action of the therapeutic effects of CBD within different disease co…”
BackgroundThe vanilloid receptor TRPV1: Role in cardiovascular and gastrointestinal protection
Peng, J., & Li, Y. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.053 · Cited by 143
Self-citationLuchicchi, A., & Pistis, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8299-0 · Cited by 143
Use of cannabidiol in anxiety and anxiety-related disorders
Skelley, J. W., Deas, C. M., Curren, Z., & Ennis, J. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.11.008 · Cited by 143
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139
Targeting cannabinoid receptor CB2in cardiovascular disorders: promises and controversies
Steffens, S., & Pacher, P. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02042.x · Cited by 137
Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017) · JCI Insight · doi:10.1172/jci.insight.93760 · Cited by 136
Vilela, L., Lima, I. V. D. A., Kunsch, É. B., Pinto, H. P. P., de Miranda, A. S., Vieira, É. L. M., de Oliveira, A. C. P., Moraes, M. F. D., Teixeira, A. L., & Moreira, F. A. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.07.014 · Cited by 134
Is the cardiovascular system a therapeutic target for cannabidiol?
Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04351.x · Cited by 131
Hallak, J. E. C., Machado‐de‐Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C. M. F., Chaves, C., Bernardo, S. A., Regalo, S. C. H., & Zuardi, A. W. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100011 · Cited by 129
The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?
Moreno, E., Cavic, M. R., Krivokuća, A., Casadó, V., & Canela, E. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00339 · Cited by 129
Wheless, J. W., Dlugos, D., Miller, I., Oh, D. A., Parikh, N., Phillips, S. E., Renfroe, J. B., Roberts, C. M., Saeed, I., Sparagana, S. P., et al. (2019) · CNS Drugs · doi:10.1007/s40263-019-00624-4 · Cited by 128
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Johal, H. S., Devji, T., Chang, Y., Simone, J. J., Vannabouathong, C., & Bhandari, M. (2020) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.1177/1179544120906461 · Cited by 120
Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice
Long, L. E., Chesworth, R., Huang, X., Wong, A., Spiro, A. S., McGregor, I. S., Arnold, J. C., & Karl, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034129 · Cited by 118
Murillo‐Rodríguez, E., Blanco‐Centurion, C., Sánchez, C., Piomelli, D., & Shiromani, P. J. (2003) · SLEEP · doi:10.1093/sleep/26.8.943 · Cited by 117
The Endocannabinoid Signaling System in the CNS: A Primer
Hillard, C. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.10.001 · Cited by 115
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Nazıroğlu, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150216222543 · Cited by 114
Use of cannabidiol (CBD) for the treatment of chronic pain
Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 114
Johnson, E. L. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.002 · Cited by 110
Allosteric Modulators of the CB 1 Cannabinoid Receptor: A Structural Update Review
Morales, P., Goya, P., Jagerovic, N., & Hernández‐Folgado, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0005 · Cited by 106
Cannabidiol in the Treatment of Epilepsy
von Wrede, R. D., Helmstaedter, C., & Surges, R. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01003-y · Cited by 105
Chemotherapy-induced nausea and vomiting: optimizing prevention and management.
Rao, K. V., & Faso, A. (2012) · PubMed Central · Cited by 100
Linares, I. M. P., Guimarães, F. S., Éckeli, Á. L., Crippa, A. C. S., Zuardi, A. W., Souza, J. D. S., Hallak, J. E. C., & Crippa, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00315 · Cited by 100
Wright, M., Ciano, P. D., & Brands, B. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0052 · Cited by 99
Yang, K. S., Galadari, S., Isaev, D. S., Petroianu, G. A., Shippenberg, T. S., & Öz, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162594 · Cited by 97
Crippa, J. A. S., Zuardi, A. W., Guimarães, F. S., Campos, A. C., Osório, F. D. L., Loureiro, S. R., SANTOS, R. G. D., Souza, J. D. S., Ushirohira, J. M., Pacheco, J. C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.20603 · Cited by 96
Wu, H., Chu, R., Wang, C., Lee, C.-Y., Lin, S., & Jan, T. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.09.012 · Cited by 94
Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability
Jacobsson, S. O. P., Rongård, E., Stridh, M., Tiger, G., & Fowler, C. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00492-5 · Cited by 94
Hsiao, Y.-T., Yi, P.-L., Li, C.-L., & Chang, F.-C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.013 · Cited by 91
Ramer, R., Rohde, A., Merkord, J., Rohde, H., & Hinz, B. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0219-2 · Cited by 91
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
Lee, C.-Y., Wey, S., Liao, M.-H., Hsu, W., Wu, H., & Jan, T. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.01.018 · Cited by 91
Endocannabinoid system: An overview of its potential in current medical practice.
Mouslech, Z., & Valla, V. (2009) · PubMed · Cited by 83
Beta Cell Death and Protection
Mandrup-Poulsen, T. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1288.005 · Cited by 82
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.
Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G., & Safe, S. H. (2011) · PubMed · Cited by 79
Kenyon, J., Liu, W. M., & Dalgleish, A. G. (2018) · Anticancer Research · doi:10.21873/anticanres.12924 · Cited by 79
Endocannabinoid Signaling Regulates Sleep Stability
Pava, M. J., Makriyannis, A., & Lovinger, D. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152473 · Cited by 75
Gallily, R., Even-Chen, T., Katzavian, G., Lehmann, D., Dagan, A., & Mechoulam, R. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000103917 · Cited by 70
Schuelert, N., & McDougall, J. J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.004 · Cited by 66
The role of different serotonin receptor subtypes in seizure susceptibility
Gharedaghi, M. H., Seyedabadi, M., Ghia, J., Dehpour, A. R., & Rahimian, R. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3757-0 · Cited by 65
Yokoe, T., Hayashida, T., Nagayama, A., Nakashoji, A., Maeda, H., Seki, T., Takahashi, M., Takano, T., Abe, T., & Kitagawa, Y. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0140 · Cited by 61
Role of the TRPV Channels in the Endoplasmic Reticulum Calcium Homeostasis
Haustrate, A., Prevarskaya, N. B., & Lehen’kyi, V. (2020) · Cells · doi:10.3390/cells9020317 · Cited by 61
Martínez-Aguirre, C., Carmona-Cruz, F., Velasco, A. L., Velasco, F., Aguado-Carrillo, G., Cuéllar‐Herrera, M., & Rocha, L. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.611278 · Cited by 61
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune ResponsePreprint
Nguyen, L. C., Yang, D., Nicolaescu, V. I., Best, T. J., Ohtsuki, T., Chen, S., Friesen, J. B., Drayman, N., Mohamed, A., Dann, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.10.432967 · Cited by 61
Leweke, F. M., Rohleder, C., Gerth, C. W., Hellmich, M., Pukrop, R., & Koethe, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.614811 · Cited by 53
Fagundo, A. B., de la Torre, R., Jiménez‐Múrcia, S., Agüera, Z., Pastor, A., Casanueva, F. F., Granero, R., Baños, R., Botella, C., del Pino‐Gutiérrez, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066387 · Cited by 49
Suraev, A. S., Grunstein, R. R., Marshall, N. S., D'Rozario, A. L., Gordon, C. J., Bartlett, D. J., WONG, K. K. H., Yee, B. J., Vandrey, R. G., Irwin, C. G., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034421 · Cited by 49
T-type Ca2+ channels and absence epilepsy
SHIN, H. (2006) · Cell Calcium · doi:10.1016/j.ceca.2006.04.023 · Cited by 39
Vigil, J. M., Stith, S. S., Diviant, J. P., Brockelman, F., Keeling, K., & Hall, B. (2018) · Medicines · doi:10.3390/medicines5030075 · Cited by 39
CB1 Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?
Mukhopadhyay, P., Rajesh, M., Bátkai, S., & Pacher, P. (2008) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.00016.x · Cited by 33
Cannabidiol presents an inverted U-shaped dose-response curve in the simulated public speaking test
Linares, I., Zuardi, A. W., Pereira, L. C. G., Queiroz, R. H. C., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. S. (2016) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(16)31702-3 · Cited by 31
Russo, E. B., Guy, G. W., & Robson, P. (2007) · ChemInform · doi:10.1002/chin.200747254 · Cited by 15
(2000) · doi:10.1002/1520-6394(2000)12:1+<2::aid-da2>3.0.co;2-4
Metadata
- Authors
- Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2022-02-06
- Volume
- 130
- Issue
- 4
- Pages
- 439-456
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W4210607766
- Cited by
- 282
- References
- 159
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.